Navigation Links
New Shire Board Member

DUBLIN, Ireland, November 2 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that Mr David Stout joined the Board as a Non Executive Director with effect from 31 October 2009.

Mr Stout has extensive pharmaceutical experience. Most recently he was President, Pharmaceutical Operations at GSK. In this position he had responsibility for pharmaceutical operations in the United States, Europe, Japan and all other International Markets. Mr Stout was also responsible for global manufacturing and global Biologics (vaccines) at GSK. Prior to that he was President of GSK's US Pharmaceuticals Business and before that SmithKline Beecham's North American Pharmaceuticals Business. Before joining SmithKline Beecham, Mr Stout worked for many years at Schering-Plough.

Mr Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit, Inc. and Airgas Inc.

Matt Emmens, Chairman of Shire commented;

"We are delighted to welcome David Stout to the Shire Board. He brings with him extensive international experience in the pharmaceutical industry, which we believe will be of great value to Shire as it continues its growth trajectory and becomes a more global company."

Notes to Editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

    For further information please contact:

    Relations    Clea Rosenfeld (Rest of the World)       +44-1256-894-160
                 Eric Rojas (North America)               +1-617-551-9715
    Media        Jessica Mann (Rest of the World)         +44-1256-894-280
                 Matthew Cabrey (North America,           +1-484-595-8248
                 Specialty Pharma)
                 Jessica Cotrone (North America, HGT)     +1-617-613-4640

SOURCE Shire Plc

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, a ... chemistry professor Jan Halámek, is taking crime scene ...   -->   ... --> --> ... have discovered a straightforward concept for identifying whether ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... new globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 at ... embark on a worldwide tour including several North American tour dates. The Exhibition ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):